Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies
Tildrakizumab 200 mg effectively treated moderate-to-severe psoriasis across diverse patient subgroups. While higher weight and PASI were associated with slightly lower PASI100 rates, significant improvements were observed, supporting its role in difficult-to-treat patients.
Authors
- Marco Manfredini (ORCID: https://orcid.org/0000-0003-3601-655X)
- Massimiliano Nicolini
- Emanuele Trovato (ORCID: https://orcid.org/0000-0001-8301-9206)
- Tommaso Bianchelli (ORCID: https://orcid.org/0000-0003-1323-0158)
- Claudia Lasagni (ORCID: https://orcid.org/0000-0002-0370-6602)
- Anna Campanati (ORCID: https://orcid.org/0000-0002-3740-0839)
- Aldo Cuccia (ORCID: https://orcid.org/0000-0002-0276-1554)
- Alessandra Cartocci (ORCID: https://orcid.org/0000-0002-1818-6275)
- Federico Bardazzi (ORCID: https://orcid.org/0000-0001-6162-2004)
- Giulia Odorici (ORCID: https://orcid.org/0000-0002-5910-8994)
- Vito Giuseppe Di Lernia (ORCID: https://orcid.org/0000-0002-8961-7108)
- Francesca Satolli (ORCID: https://orcid.org/0000-0003-1610-9249)
- Giulia Rech
Institutions
- University of Siena (IT)
- University of Modena and Reggio Emilia (IT)
- Marche Polytechnic University (IT)
- University of Parma (IT)
- University of Ferrara (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Ospedale Santa Maria (IT)
- Ospedale San Donato (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto Nazionale di Riposo e Cura per Anziani (IT)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1007/s13555-025-01442-x
- Citations
- 5
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 3.99